June 2023 8
CMV Management in the Post-DNA Polymerase Inhibitor Era
30. Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF,
Cordonnier C, et al. Maribavir for refractory cytomegalovirus
infections with or without resistance post-transplant: results
from a phase 3 randomized clinical trial. Clin Infect Dis.
2022;75(4):690-701.
31. Shafat MS, Mehra V, Peggs KS, Roddie C. Cellular Therapeutic
Approaches to cytomegalovirus infection following allogeneic
stem cell transplantation. Front Immunol. 2020;11:1694.
32. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA,
Ramos CA, et al. Off-the-shelf virus-specific T cells to treat BK
virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus,
and adenovirus infections a›er allogeneic hematopoietic stem-
cell transplantation. J Clin Oncol. 2017;35(31):3547-57.
